I-ADHD isifo esiqhelekileyo, esoloko siphathwa ngayo kunye nezikhuthazo, njengeRitalin (methylphenidate) kunye ne-Adderall, okanye iStrattera . Nangona uncedo kubantwana abaninzi, ngokuqinisekileyo ukubafumana ukuba bathathe amayeza abo imihla ngemihla banokubakho umzabalazo, ngokukodwa ukususela ekubeni i-ADHD imishanguzo sele ikhona kwifilisi kunye nefomsule ifomu.
Ikhofi kwi-ADHD
Ukusela ikofi akuyona enye enye iipilisi esizithethayo, nangona ibalaselisa ezinye zezibonelelo zonyango ze-ADHD abazali abathile bazame.
Ukunika abantwana nge-caffeine ye-ADH akuyona ingcinga entsha.
Ucwaningo luka-1975 kwi-American Journal of Psychiatry lubhekisele kwi-caffeine, i-methylphenidate (iRitalin) kunye ne-d-amphetamine (i-Dexedrine), kwaye ifumene ukuba ngelixa i-caffeine yayingcono kune-placebo ekuphatheni abantwana nge-ADHD, zombini izidakamizwa zanikezela ukuphucula ngaphezu kwe-placebo kunye ne-caffeine.
Bonke bebonke, kubonakala izifundo ezi-6 ezilawulwayo zenziwa kwimiphumo ye-caffeine kubantwana abane-ADHD ngawo-1970, kwaye abazange babonise ubungqina obukholisayo bokuzuza.
Inqaku kwi-Experimental & Clinical Psychopharmacology yada yaphakamisa ukuba "i-caffeine ibonakala iphinde iphuculise ukusebenza kakuhle nokunciphisa ixesha lokusabela kubafundi abasemgangathweni abadla ngokutya i-caffeine kodwa abaphuculanga ngokuqhubekayo ukusebenza kwabantwana abanenkinga yokungahambi kakuhle."
Kubalulekile ukuqaphela ukuba i-caffeine yiphilisi nayo, nangona kunjalo.
Kuyaziwa ngokuba ngumlutha kwaye kubangele iimpawu zokuhoxisa abantu abaninzi. Ngoko, nangona ingaqwalaselwa ngenye indlela okanye engeyiyo emgangathweni unyango lwe-ADHD, akunjalo ngokwenene.
Kwaye akusebenzi, ngoko makhe sijonge ezinye iindlela zokufumana amachiza amayeza abantwana abangenako ukugwinya iipilisi.
Quillivant XR
Kukho iindawo ezininzi zokufumana abazali abangenakufumana abantwana babo ukugwinya iipilisi kunye neepsules.
Hayi, akusiyo uSukutrana, isiqwenga seRitalin abantu bathetha ngazo iminyaka. Esikhundleni salokho, inguqu ebenzayo ende yeRitalin ifumaneka njengesisombululo somlomo.
I-Quillivant XR yavunywa yi-FDA ngo-2012 kubantwana abaphakathi kweminyaka eyi-6 kunye ne-12 kunye ne-ADHD. I-dose yokuqala ephakanyisiweyo ingama-20mg kwaye ekubeni ukuxinwa ngu-25mg nge-5 ml, okuya kulingana no-4ml okanye ngaphantsi kwe-teaspoon.
Isilinganisi sinokunyuswa ngo-10mg ukuya kwi-20mg nganye iveki ide isebenze kakuhle okanye uqala ukubona imiphumo emibi kakhulu, ukuya kwi-dosage ye-60mg yansuku zonke.
Adzenys XR ODT
Ukuba kunzima ukufumana umntwana wakho ukuba athathe imishanguzo ye-ADHD yamanzi, kukho enye enye indlela, ithebhulethi yokutshatyalaliswa ngomlomo.
I-Adzenys XR ODT yi-amphetamine esekelwe ukukhululwa kwithebhulethi yomonakalo ochithwe ngomlomo ovunywe kwiintsana ezine-ADHD.
Kukhona 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, iipilisi ze-18.8 mg, i-dose yokuqala ekhuthazwayo yi-6.3mg ekuseni, ngesantya esiphezulu se-18.8mg.
Ezinye iindlela zokusetyenziswa kweepilisi zokuPhatha i-ADHD
Amanye amayeza e-ADHD afumaneka kwiintsana ezingakwazi ukugwinya iipilisi kunye neepssile ziquka:
- U-Daytrana - isicatshulwa saseRitalin esilula ixesha elide
- Isisombululo somlomo saseMethylin - ifom ye-Ritalin (i-methylphenidate)
- I-QuilliChew ER - ifomu lokukhululwa leRitalin (i-methylphenidate)
- I-ProCentra-ifom ye-short-acting ye-Dexedrine (dextroamphetamine)
Kodwa khumbula ukuba ukuthatha abantwana ukuba bathathe i- Adderall XR okanye i- Focalin XR , ezo zombini ezikhoyo njengeefowuni ezingavulwa kunye nokufafaza ekudleni, akunjalo oko kunzima. Futhi iVasse capsules inokuvulwa kuphela kwaye ixutywe ngamanzi.
Ukuba nezinye iinketho zinokuba luncedo, nangona kunjalo. Ukuba umntwana wakho unenkathazo ekuthatha ii-capsules ze-ADHD, nangona xa uvula, cela umntwanantso wezilwanyana malunga ne-liquid, i-ODT, kunye neendlela ezinokutshintshwa kwala mayeza.
Ubuncinane de bafunde ukugwinya iipilisi .
Imithombo:
I-American Academy ye-Pediatrics Guideline Practice Guideline. I-ADHD: Isikhokelo seNkcazo yokuSebenza, ukuVavanya kunye nokuPhathwa kweNkcazo-Ukulahleka / ukuxhatshazwa kwengxaki kwi-Children and Adolescents. Pediatrics. 108 (4): 1033.
I-Adzenys XR ODT Ukuchaza ulwazi. Ukuhlaziywa ngo-01/2016
I-QUILLIVANT XR Ukuchonga ulwazi. Ukuhlaziywa 09/2012